Impact of glycan linkage to staphylococcus aureus wall teichoic acid on langerin recognition and langerhans cell activation by Hendriks, A. et al.
Impact of Glycan Linkage to Staphylococcus aureus Wall Teichoic
Acid on Langerin Recognition and Langerhans Cell Activation
Astrid Hendriks, Rob van Dalen,□ Sara Ali,□ David Gerlach, Gijsbert A. van der Marel,
Felix F. Fuchsberger, Piet C. Aerts, Carla J.C. de Haas, Andreas Peschel, Christoph Rademacher,
Jos A.G. van Strijp, Jeroen D.C. Codée, and Nina M. van Sorge*
Cite This: ACS Infect. Dis. 2021, 7, 624−635 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Staphylococcus aureus is the leading cause of skin and soft
tissue infections. It remains incompletely understood how skin-resident
immune cells respond to invading S. aureus and contribute to an effective
immune response. Langerhans cells (LCs), the only professional antigen-
presenting cell type in the epidermis, sense S. aureus through their pattern-
recognition receptor langerin, triggering a proinflammatory response.
Langerin recognizes the β-1,4-linked N-acetylglucosamine (β1,4-GlcNAc)
but not α-1,4-linked GlcNAc (α1,4-GlcNAc) modifications, which are added
by dedicated glycosyltransferases TarS and TarM, respectively, on the cell
wall glycopolymer wall teichoic acid (WTA). Recently, an alternative WTA
glycosyltransferase, TarP, was identified, which also modifies WTA with β-
GlcNAc but at the C-3 position (β1,3-GlcNAc) of the WTA ribitol
phosphate (RboP) subunit. Here, we aimed to unravel the impact of β-
GlcNAc linkage position for langerin binding and LC activation. Using
genetically modified S. aureus strains, we observed that langerin similarly recognized bacteria that produce either TarS- or TarP-
modified WTA, yet tarP-expressing S. aureus induced increased cytokine production and maturation of in vitro-generated LCs
compared to tarS-expressing S. aureus. Chemically synthesized WTA molecules, representative of the different S. aureus WTA
glycosylation patterns, were used to identify langerin-WTA binding requirements. We established that β-GlcNAc is sufficient to
confer langerin binding, thereby presenting synthetic WTA molecules as a novel glycobiology tool for structure-binding studies and
for elucidating S. aureus molecular pathogenesis. Overall, our data suggest that LCs are able to sense all β-GlcNAc-WTA producing
S. aureus strains, likely performing an important role as first responders upon S. aureus skin invasion.
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Staphylococcus aureus is a Gram-positive bacterium that
transiently colonizes an estimated 20% of the human
population at different sites of the body, including the
nasopharynx, skin, and gastrointestinal tract.1 The skin is a
common entry site for S. aureus, making it the leading cause of
skin and soft tissue infections (SSTIs).2 Consequently, efficient
and rapid recognition of invading S. aureus by resident skin
immune cells is critical for local eradication. When local
immune defense fails, bacteria can disseminate into deeper
tissues or even cause systemic infections, which are associated
with high overall disease burden and mortality. The high
recurrence of S. aureus SSTIs indicates that protective immune
memory is defective, although the underlying reasons remain
elusive. Indeed, there are no clear correlates of protection
known for S. aureus, which has been a challenging aspect for
vaccine development.3 A complete understanding of the local
skin immune response to S. aureus may identify factors that
protect the host from (re)infection, thereby providing critical
insight for the development of a future S. aureus vaccine.
The skin contains a large arsenal of immune cells, which
reside in different compartments within the skin. Langerhans
cells (LCs), a highly specialized macrophage subset with
dendritic cell-like functions, are the main antigen-presenting
cells within the epidermis.4 Human LCs appear to have an
important dual role in maintaining skin homeostasis by
balancing both tolerogenic responses toward skin commensals
as well as pro-inflammatory responses to invading patho-
gens.5−10 However, the ability of LCs to recognize and respond
to invading bacteria remains elusive due to their restricted
expression of Toll-like receptors.11,12 C-type lectin receptors
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(CLRs) constitute a family of pattern-recognition receptors
(PRRs), which are dedicated to the recognition of glycans.13 A
signature CLR of LCs is langerin (CD207).14 Langerin is a
trimeric type II transmembrane receptor with specificity for
sulfated and mannosylated glycans as well as β-glucans, which
are recognized in a calcium-dependent manner.15−17 The
direct downstream effects of receptor activation remain to be
determined because langerin only contains a short cytoplasmic
tail without classical signaling motifs.14 It is generally assumed
that langerin-bound cargo is endocytosed and processed for
antigen presentation to CD4 T cells via major histocompat-
ibility complex class II (MHC-II).18−20
Recent work demonstrated that langerin allows human LCs
to discriminate S. aureus from other staphylococci through a
specific interaction with glycosylated wall teichoic acid
(WTA).21 WTA is a major component of the Gram-positive
bacterial cell wall and a well-known immunogenic antigen for
opsonic antibodies targeting S. aureus.22−24 S. aureus WTA
consists of a polymerized ribitol phosphate (RboP) backbone
that can be codecorated with positively charged D-alanine and
N-acetylglucosamine (GlcNAc) residues. D-Alanylation of
WTA is highly regulated and impacts bacterial surface charge,
thereby providing protection from host cationic antimicrobial
peptides (AMPs) and the lipopeptide antibiotic daptomy-
cin.25−28 WTA glycosylation can be mediated by different
glycosyltransferases, resulting in distinct WTA glycoforms.
Three different WTA glycoforms have been identified in S.
aureus, which differ in the configuration and position of
GlcNAc linkage. Langerin binding to S. aureus is conferred by
β-1,4-GlcNAc modified WTA, which requires the glycosyl-
transferase TarS that is present in nearly all S. aureus
strains.29,30 Approximately 30% of S. aureus strains derived
from nasal isolates coexpress tarM, which encodes a
glycosyltransferase that modifies WTA with α-1,4-GlcNAc.29,31
Although α-1,4-GlcNAc did not confer langerin binding, it
attenuated langerin binding to β-1,4-GlcNAc WTA, likely as a
result of substitution or steric hindrance. This suggests that S.
aureus clones coexpressing tarM/tarS can alter WTA
glycosylation to evade innate immune activation by LCs.21
Interaction between β-1,4-GlcNAc expressing S. aureus and
langerin increased pro-inflammatory cytokine production by in
vitro-generated LCs and in the skin of human langerin-
transgenic mice after epicutaneous infection, suggesting a
contribution to antibacterial host defense.21 Overall, WTA
glycosylation impacts the ability of LCs to sense invading S.
aureus and mount a local immune response.21
In addition to TarM and TarS, a third glycosyltransferase,
TarP, has recently been identified.32 TarP modifies the WTA
backbone with β-linked GlcNAc residues similar to TarS but at
the C3 position of RboP instead of C4. TarP is always
coexpressed with tarS and is associated with, but not limited
to, healthcare-associated and livestock-associated MRSA
strains belonging to clonal complexes 5 and 398.32,33 TarP
can functionally replace TarS with regard to β-lactam
resistance and phage susceptibility via the decoration of
WTA with β-GlcNAc moieties.30,32 However, whether the
same applies to immune recognition remains to be fully
elucidated. For example, TarP-modified WTA displayed
Figure 1. WTA β-GlcNAcylation by TarS and TarP confers langerin binding to S. aureus. Binding of recombinant human langerin-FITC (A) to
N315 WT, ΔtarS, ΔtarP, ΔtarPS, ΔtarPS + ptarS, and ΔtarPS + ptarP at a fixed concentration of 5 μg/mL and (B) to the indicated N315 strain
panel using a concentration range of langerin-FITC (0.6−40 μg/mL). (C, D) Binding of FITC-labeled recombinant human langerin wild-type and
N288D/K313I double SNP variant (10 μg/mL) to (C) RN4220 WT, ΔtarMS, ΔtarMS + ptarS, ΔtarMS + ptarP, and ΔtarMS + ptarM and (D)
the N315 mutant panel (mentioned above). Data are depicted as geometric mean fluorescence intensity (FI) + standard error of mean (SEM) of
biological triplicates. **p < 0.01, ***p < 0.001, ****p < 0.0001.
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attenuated immunogenicity in mice compared to TarS-
modified WTA and comodification of WTA by TarP may
lower S. aureus antibody recognition despite the presence of
antibodies to both WTA glycoforms in serum from healthy
individuals.24,33
In this study, we assessed the impact of TarP-mediated
WTA glycosylation on langerin recognition and responses, i.e.
antigen uptake and cytokine production, of in vitro-generated
LCs. We describe that langerin-mediated recognition and
uptake of S. aureus is similar for strains expressing β-1,3-
GlcNAc WTA or β-1,4-GlcNAc WTA. Despite similar
recognition and uptake, LC cytokine production was more
pronounced upon interaction with tarP-expressing bacteria
compared to tarS-expressing bacteria. Finally, employing
synthetic WTA molecules with specific GlcNAc modifica-
tions,34 we demonstrate that β-GlcNAc WTA is sufficient but
not exclusively required for S. aureus binding to langerin-
expressing cells. Overall, we provide evidence that LCs are able
to sense and respond to all S. aureus strains that produce β-
GlcNAc-modified WTA. Furthermore, the use of chemically
synthesized WTA structures provides a valuable toolbox to
study the interaction between host immune molecules such as
CLRs and S. aureus WTA in more detail.
■ RESULTS
TarP and TarS Both Confer Binding of Human
Langerin to S. aureus. TarP can replace several key
functions of TarS, including resistance to β-lactam antibiotics
and susceptibility to siphophage infection.32 In contrast,
decoration of WTA with β-1,3-GlcNAc in addition to or
instead of β-1,4-GlcNAc may impact immune detection by
antibodies.24,32 We recently identified that β-1,4-GlcNAc WTA
Figure 2. β-GlcNAc-modified WTA is sufficient to confer langerin binding. (A) Schematic overview of the synthetic WTA structures and in vitro
glycosylation by recombinant TarS, TarP, or TarM. (B) Binding of recombinant human langerin-FITC (0.4−25 μg/mL) to RboP hexamers alone
(RboP backbone) or after in vitro glycosylation by TarS, TarP, or TarM. (C) Binding of recombinant human langerin-FITC (0.4−25 μg/mL) to
RboP dodecamers alone (RboP backbone) or after in vitro glycosylation similar to RboP hexamers. Binding to β-GlcNAc WTA was assessed in the
absence and presence of EGTA (10 mM). Data for panel B and C are shown as fluorescence signal + SEM of three independent experiments and
were compared with the negative control (buffer). *p < 0.05, ****p < 0.0001.
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is specifically detected by the human innate receptor
langerin.21 To assess whether human langerin was also able
to detect tarP-expressing S. aureus strains, we employed a
FITC-labeled recombinant construct of the extracellular
carbohydrate domain (ECD) of human langerin (langerin-
FITC).35 Using S. aureus strain N315 that naturally expresses
both tarS and tarP,32 we observed that langerin binding was
significantly impaired upon deletion of both glycosyltrans-
ferases (ΔtarPS), but not in either of the single mutant strains
(Figure 1A). Subsequent complementation of the ΔtarPS
double mutant with a plasmid containing either tarS or tarP
restored the binding to recombinant langerin-FITC (Figure
1A). This observation in differential langerin binding among
the N315 mutant panel persisted over a 100-fold concentration
range of langerin-FITC, although at higher concentrations,
langerin-FITC also showed significant binding to the ΔtarPS
strain (Figure 1B). Binding to the N315 ΔtarPS strain was also
dependent on the langerin carbohydrate recognition domain
(CRD) because the interaction could be blocked by addition
of mannan (Supporting Figure 1B). Similar binding experi-
ments were additionally performed in S. aureus strain RN4220,
which naturally coexpresses tarS and tarM, but not tarP. As
previously reported,21 langerin binding to RN4220 wild-type
was significantly reduced in the ΔtarMS double mutant
(Figure 1C). Binding could be restored by complementation
with either tarS or tarP but not tarM (Figure 1C). For the
N315 and RN4220 strain panels, expression of the correct
WTA glycoform was confirmed through binding of specific
mAbs (Supporting Figure 1A24). Overall, langerin binds to
TarP-modified WTA independent of strain background.
While it was apparent that langerin binding to S. aureus
required either TarP or TarS, it was not clear whether the
receptor bound the two different modifications in a similar
way. Previously, we showed that langerin binding to S. aureus
was abrogated when a naturally occurring double SNP was
introduced into the human langerin ECD.36 Using these same
langerin SNP constructs, we observed a similar loss of binding
to TarP-expressing S. aureus (Figure 1C, D). These data
suggest that the WTA β-1,3-GlcNAc moiety created by TarP is
similarly dependent on these two residues in the CRD of
langerin compared to the β-1,4-GlcNAc moiety on WTA
generated by TarS.
WTA β-GlcNAc is Sufficient to Confer Langerin
Binding. TarP-expressing S. aureus can bind langerin in a
similar way to S. aureus expressing TarS. However, we also
observed significant residual binding in the ΔtarPS background
at higher langerin concentrations (Figure 1B). We therefore
asked whether WTA-β-GlcNAc is sufficient to confer binding
to S. aureus or whether additional bacterial cofactors are
required. The isolation of WTA from the bacterial cell wall is
challenging; the procedure is labor intensive, but moreover, the
instability and variation in isolated WTA creates difficulties for
assay reproducibility. Therefore, we used our previously
developed system,24 where chemically synthesized WTA
backbone fragments of defined length are glycosylated by
specific recombinant Tar enzymes in vitro (Figure 2A). With
Figure 3. Binding and internalization of β-GlcNAc-WTA-coated beads by langerin-expressing THP-1 cells. (A) Binding of FITC-labeled beads,
coated with unglycosylated or in vitro glycosylated RboP hexamers, to THP-1 cells transfected with human langerin or empty vector at a bead-to-
cell ratio of 1. Adherence is represented by percent of FITC+ cells. (B) Proportion of adherent β-GlcNAc WTA beads that is internalized by
Langerin + THP-1 cells. (C) Confocal microscopy images (40×) of β-GlcNAc WTA beads (FITC-labeled: green) bound to and internalized by
Langerin+THP-1 cells (WGA-Alexa 647: red, DAPI: blue). Vertical lines correspond to cross section of z-stack on the right, horizontal lines to
cross section below, scale bars correspond to 25 μm. For panels A and B, graphs represent mean + SEM of biological triplicates, ****p < 0.001.
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this robust system, we have previously studied the interaction
of specific WTA glycoforms and antibodies in a reproducible
and low background manner.24 In this study, we used both
hexameric and dodecameric RboP backbones to assess the
influence of WTA chain length on langerin binding. Differently
glycosylated biotinylated WTA structures were coated on
streptavidin-coated ELISA plates and incubated with a
concentration range of recombinant langerin-FITC. Only
Figure 4. S. aureus WTA glycoform affects binding to and activation of in vitro-generated LCs. (A) Binding of FITC-labeled beads, coated with in
vitro glycosylated RboP dodecamers, to muLCs at bead-to-cell ratios of 1, 5, and 10. Bead adherence is displayed as percent of FITC+ cells. (B)
Binding of FITC-labeled beads coated with TarS- or TarP-modified RboP dodecamers to muLCs at a bead-to-cell ratio of 10 in the absence
(similar to A) or presence of mannan (20 μg/mL) or anti-langerin blocking antibody (20 μg/mL). (C) Binding of FITC-labeled RN4220 ΔtarMS
complemented with plasmid-expressed tarS, tarP, or tarM to muLCs at a bacteria-to-cell ratio of 1. Bacterial binding is represented by percent of
FITC+ cells. (D) Surface expression of activation marker CD86 and maturation marker CD83 by muLCs after 24 h of stimulation with γ-irradiated
RN4220 ΔtarMS complemented with plasmid-expressed tarS, tarP, or tarM at bacteria-to-cell ratios of 1, 10, and 50. (E) Concentration of IL-8 and
TNFα in the supernatant of muLCs described in D. The data for all panels represent mean + SEM of biological triplicates. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001.
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00822
ACS Infect. Dis. 2021, 7, 624−635
628
wells coated with β-1,4-GlcNAc- and β-1,3-GlcNAc-glycosy-
lated WTA structures mediated concentration-dependent
binding to langerin and no binding was observed to the
RboP backbone or α-1,4-GlcNAc-glycosylated WTA (Figure
2B, C). In addition, langerin binding was increased when the
WTA backbone was extended from 6- to 12-RboP units
(Figure 2B, C). Interaction between recombinant langerin-
FITC and synthetic WTA was completely abolished in the
presence of EGTA (Figure 2C), which scavenges calcium ions
required for receptor binding. Langerin binding likely requires
more than two β-GlcNAc residues, because we could not
detect binding to a fully synthetic WTA molecule consisting of
hexameric RboP backbone and β-1,4-GlcNAc coupled to the
third and terminal RboP subunit (Supporting Figure 2A, B). In
contrast, monoclonal antibodies specific for either α-GlcNAc-
WTA or β-GlcNAc-WTA were able to bind the fully synthetic
WTA structures (Supporting Figure 2C). This does not only
indicate that fully synthetic structures were coated correctly to
the wells but also underlines the differences in minimal binding
requirements to glycosylated WTA between antibodies and
langerin. Overall, these data confirm that β-GlcNAc WTA is
sufficient to confer interaction with langerin and does not
require the presence of D-alanine residues on WTA nor
additional bacterial factors.
We also assessed binding of beads, coated with the
differently glycosylated WTA oligomers, to surface-expressed
langerin on transfected THP-1 cells. FITC-labeled beads were
coated with synthetic glycosylated WTA hexamers, and coating
was verified by binding of monoclonal antibodies specific for
either α-GlcNAc or β-GlcNAc WTA (Supporting Figure 3).
We observed strong binding of β-GlcNAc WTA beads,
modified by either TarS or TarP, to langerin-expressing
THP-1 cells but not empty vector control cells (Figure 3A).
In addition to binding, Langerin + THP-1 cells internalized the
majority of adhered beads as assessed by flow cytometry
(Figure 3B) and confocal microscopy (Figure 3C). No
apparent differences in receptor binding or cellular uptake
were observed for TarS- and TarP-modified WTA beads in this
system, suggesting that both modifications confer a similar
function with regard to langerin interaction.
Expression of β-GlcNAc WTA Contributes Signifi-
cantly to the Interaction between S. aureus and LCs.We
have recently shown that langerin significantly contributes to
the interaction between S. aureus and primary human LCs.21 In
addition, in vitro-generated muLCs were used as an LC cell
model to demonstrate the impact of langerin recognition on
activation of APCs.21 Here, we again used muLCs to study the
binding of surface-expressed langerin to β-GlcNAc WTA
modifications mediated by TarS or TarP. In line with the
THP-1 binding experiments, muLCs also specifically bound to
β-GlcNAc WTA beads, irrespective of linkage to C3 (TarP) or
C4 (TarS) (Figure 4A). At a bead-to-cell ratio of 10, beads
decorated with β-1,3-GlcNAc WTA adhered significantly
better compared to beads decorated with β-1,4-GlcNAc
WTA (Figure 4A). This observed binding was mediated by
the presence of langerin, as we were able to block the binding
of muLCs to β-GlcNAc WTA beads by addition of mannan, a
ligand for langerin, or specific langerin-blocking monoclonal
antibodies (Figure 4B). These data show that β-GlcNAcylated
WTA is sufficient to confer binding to muLCs and does not
require bacterial cofactors.
Next, we assessed whether β-GlcNAc WTA was necessary
for S. aureus binding to muLCs. For these experiments we used
the RN4220 ΔtarMS background where tarM, tarS and tarP
are individually and constitutively expressed from a com-
plementation plasmid. We observed an approximately 3-fold
higher binding to muLCs by S. aureus strains expressing β-
GlcNAc WTA compared to α-GlcNAc-WTA producing S.
aureus (Figure 4C). However, even in the absence of β-
GlcNAc WTA, S. aureus was able to adhere to muLCs.
Furthermore, binding of β-GlcNAc WTA producing S. aureus,
but not α-GlcNAc producing S. aureus, to muLCs was
significantly blocked by addition of mannan (Figure 4C).
These results indicate that the interaction between langerin
and β-GlcNAc WTA is an important determinant, although
not exclusively required, for S. aureus binding to LCs.
To assess the downstream effects of langerin-mediated
binding of S. aureus to muLCs and potential differences herein
between β-1,4-GlcNAc-WTA versus β-1,3-GlcNAc-WTA
producing S. aureus, we stimulated muLCs for 24 h with
gamma-irradiated RN4220 ΔtarMS, complemented with either
plasmid-expressed tarS, tarP or tarM. Surface expression of
activation markers CD86 and CD83 increased in a dose-
dependent manner in response to all three strains. Expression
of CD86 and CD83 was highest in response to tarP-
complemented S. aureus and differed significantly from tarS-
complemented S. aureus (Figure 4D). The production of IL-8
and TNF-α showed a similar pattern, where all three strains
induced a dose-dependent cytokine response with highest
cytokine levels in response to tarP-complemented S. aureus
(Figure 4E). In line with previous results, tarM-complemented
S. aureus showed the lowest activation of muLCs, both in
surface expression of CD86 and CD83, as well as cytokine
production. This data suggests that besides the known effect
between α-GlcNAc-WTA and β-GlcNAc-WTA, there could be
additional differences in langerin-mediated LC activation
between β-1,3-GlcNAc-WTA and β-1,4-GlcNAc-WTA.
■ DISCUSSION
LCs are among the first responders upon invasion of S. aureus
into the skin, contributing to early initiation of pro-
inflammatory responses and recruitment of neutrophils. At
the molecular level, langerin is an important sensor of specific
S. aureus cell wall constituents, i.e. β-GlcNAcylated WTA,
which can be mediated by the housekeeping glycosyltransfer-
ase TarS and the accessory enzyme TarP.21,32 Using a
combination of recombinant langerin and langerin-transfected
cell lines, genetically-modified S. aureus strains and in vitro
generated LCs, we demonstrate that the interaction between
langerin and tarP-expressing S. aureus results in similar binding
but quantitatively different immunological responses. More-
over, comparing the binding of beads coated with synthetic
glycosylated WTA oligomers and S. aureus modified strains
emphasized that the interaction between LCs and S. aureus is
largely, but not solely, dependent on the expression of β-
GlcNAc WTA.
Binding of recombinant langerin to S. aureus was abrogated
in bacteria that lack WTA glycosyltransferases, i.e.
N315ΔtarPS and RN4220ΔtarMS bacteria. However, at
higher concentrations, residual langerin binding to these
WTA-deglycosylated strains was still observed, suggesting the
presence of a second, currently unidentified minor ligand for
langerin on the S. aureus surface. This observed binding was
specific, as the binding was saturable and was inhibited by
addition of mannan (Supporting Figure 1B). S. aureus
expresses a wide variety of surface proteins that contribute to
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skin colonization and infection.37 Interestingly, some of these
proteins, such as the serine-aspartate repeat (SDR) proteins
and SraP, are heavily glycosylated,38−40 thereby representing
potential targets for langerin in addition to β-GlcNAc WTA.
The toolbox of synthetic WTA fragments allowed us to gain
more insights into the binding requirements of langerin to
glycosylated WTA. Following current consensus, the WTA
backbone consists of up to 40 repeating units of RboP that can
be co-decorated with D-alanine and GlcNAc residues.41 The
synthetic RboP polymers used here are only modified with
GlcNAc and do not contain D-alanine residues. Consequently,
we conclude that D-alanylation of WTA is dispensable for
langerin binding in our assays, although we cannot rule out
that the interaction would be affected by the presence of D-
alanine. Also, when expressed by S. aureus, the absence or
presence of D-alanine does not seem to impact langerin binding
(Supplementary Figure 1C). In addition, we observed a strong
impact of GlcNAc abundance on langerin binding; doubling
the length of the synthetic WTA backbone enhanced langerin
binding, which is most likely explained by an increased number
of GlcNAc moieties following in vitro glycosylation. Fur-
thermore, we did not observe langerin binding to fully defined
WTA structures, which only contained two β-GlcNAc
modifications (Supporting Figure 2B). This could be due to
a limited sensitivity of our assay. Alternatively, it may indicate
that langerin requires more than two β-GlcNAc moieties or
differently spaced β-GlcNAc moieties to interact. In contrast,
two GlcNAc moieties are sufficient for antibodies to interact
with WTA (Supporting Figure 2C). Currently, not much is
known about the regulation of WTA biosynthesis and
glycosylation, although both the length of the WTA backbone
as well as the expression of glycosyltransferases are believed to
be affected by environmental cues. In the skin, activation of the
Agr regulon results in increased WTA expression on the
surface.42 Additionally, TarS-mediated WTA glycosylation
increases under infection conditions at the expense of TarM-
or TarP-mediated glycosylation, which dominate WTA
glycosylation under in vitro growth conditions.32,43,44 Con-
sequently, more β-1,4-GlcNAc moieties are produced in vivo,43
which would greatly enhance receptor avidity of langerin and
impact its function.15
TarP can replace TarS in several key processes, including β-
lactam resistance.30,32 However, whether the same applies to
immune recognition still remains to be fully clarified. In mice,
TarP-modified WTA appeared less immunogenic as compared
to TarS-modified WTA.32 Previous work has shown the
existence of cross-reactive human antibodies to both β-GlcNAc
moieties, while other antibodies seem to be more exclusively
directed toward β-1,4-GlcNAc.24 Until now, no studies have
assessed the potential discrimination between tarS- and tarP-
expressing S. aureus strains by innate immune cells. From our
cell-based assays, β-1,3-GlcNAc-modified WTA has a similar
ability to bind langerin compared to β-1,4-GlcNAc-modified
WTA. However, LC activation as detected by cytokine
production appears to be higher in response to tarP- versus
tarS-expressing S. aureus strains. This observed difference in
LC activation between TarS- and TarP-modified WTA was
only observed at higher bacteria to cell ratios. Given the
estimated density of LCs of approximately 1000 cells per mm2
in human skin,45 this ratio does not seem impossible to reach
in vivo, especially when bacteria are able to grow out although
it remains difficult to judge which conditions are most
reflecting physiologically relevant conditions. Nevertheless,
this finding potentially underlines an important difference in
the stimulatory capacity of both modifications, where β-1,3-
GlcNAc is more immunostimulatory for innate responses,
whereas β-1,4-GlcNAc is dominant for adaptive antibody
recognition. One explanation for this could be the difference in
glycosylation between both glycosyltransferases. TarP modifies
the RboP backbone with GlcNAc moieties at a higher
efficiency than TarS, which could subsequently enhance
receptor clustering and internalization by LCs. Moreover,
glycosylation by TarS or TarP differentially affects D-
alanylation of WTA, resulting in overall charge differences.32
As a consequence, TarP-mediated glycosylation might
negatively affect antigen-presentation by APCs due to
decreased zwitterionic charge properties. As a result, T cell
responses and T cell-dependent B cell responses to TarP-
modified WTA may be hampered. Furthermore, T cell-
independent B cell responses to TarP-modified WTA could
be affected as well, via decreased cross-linking of the B cell
receptor. However, more research is needed to support this
hypothesis, and the synthesis of WTA oligomers with added D-
alanine modifications will serve as an excellent tool to study
this.
Our results underline the ability of muLCs to detect and
internalize S. aureus that express β-GlcNAc on their surface. In
line with previous work, we observed that S. aureus-langerin
interaction increased surface expression of activation markers
CD86 and CD83 and enhanced the production of pro-
inflammatory cytokines such as IL-8. Cytokine production was
also increased upon epicutaneous infection of human langerin
transgenic mice with tarS-expressing S. aureus.21 Although an
increased IL-8 response would generally serve to recruit
neutrophils to the site of infection to promote rapid
eradication of invading S. aureus, we did not observe a
significant reduction in bacterial load at the experimental
conditions tested using this model.21 It therefore remains to be
elucidated whether and how the interaction between human
langerin and WTA would contribute to LC-mediated
immunity against S. aureus. Besides processes such as antigen
uptake and presentation to CD4+ T cells, little is known about
direct downstream responses of langerin.18−20,46 Moreover, a
lack of robust models, including limited access to human skin
explants, differences in langerin ligand specificity17 and
immune cell subsets in commonly used experimental
animals,47 represent significant challenges to study immature
LC function. The synthetic WTA oligomers used here could
represent a robust tool to specifically study downstream effects
of langerin receptor binding, and could even be used in
combination with appropriate TLR stimulation to unravel LC
responses in response to specific langerin-TLR triggers.48
Overall, langerin senses all β-GlcNAc WTA-producing S.
aureus strains, which contributes to but is not exclusively
required for recognition by LCs. In addition, we suspect the
existence of a second langerin ligand on the surface of S.
aureus. It is currently difficult to dissect the functional
consequences of LCs responses in more relevant biological
systems. In addition, we also lack knowledge on in vivo
expression of WTA glycosyltransferases, the resulting WTA
glycoform and the spatial distribution across the bacterial cell
wall, which all impact interaction and responses triggered by
CLRs such as langerin. Future research will need to elucidate
the impact of the S. aureus WTA glycoform on the ability of
LCs in situ to sense invading S. aureus in the skin, a frequent
point of entry, and whether this interaction aids in prevention
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of bacterial dissemination by mounting an effective local
response.
■ CONCLUSION
Here, we show that LCs, the main antigen-presenting cells in
the skin, sense all S. aureus strains that express β-GlcNAc
WTA, which is conferred by glycosyltransferases TarS as well
as the recently described TarP through the C-type lectin
receptor langerin. Langerin binding increased bacterial uptake,
LC maturation, and the production of pro-inflammatory
cytokines such as neutrophil chemoattractant IL-8. Despite
similar interaction with langerin, LC activation is more
pronounced in response to β1,3-GlcNAc-expressing versus
β1,4-GlcNAc-expressing S. aureus, suggesting different activa-
tion pathways related to specific glycan linkage. Future studies
may be able to unravel this linkage-specific activation using
chemically synthesized WTA oligomers, which we demon-
strated to be a valuable novel glycobiology tool to study
langerin-WTA binding requirements. Furthermore, these stable
WTA oligomers may pave the way for future crystallography
studies to further characterize WTA-langerin interaction at the
atomic level. In summary, our study provides insight into the
relevance of unique S. aureus WTA glycoforms for immune
interactions in specific human tissues. Future studies will
undoubtedly benefit from the chemically synthesized WTA
oligomers used here to further our understanding of S. aureus
molecular pathogenesis.
■ METHODS
Bacterial Strains and Culture Conditions. All plasmids
and strains used in this study are listed in Table S1. Bacteria
were grown overnight in 5 mL of Todd-Hewitt broth (THB;
Oxoid) at 37 °C with agitation. Growth medium was
supplemented with 10 μg/mL chloramphenicol (Sigma) for
plasmid-complemented S. aureus strains. Overnight cultures
were subcultured the next day in fresh THB and grown to a
midexponential growth phase, corresponding to an optical
density of 0.6−0.7 at 600 nm (OD600).
Generation of Complemented N315 ΔtarPS Strains.
Plasmids containing the shuttle vector RB474 with full-length
copies of tarS or tarP as inserts were isolated from
complemented RN4220 ΔtarMS strains,49 and transformed
into Escherichia coli DC10B by heat shock. Competent S.
aureus N315 ΔtarPS cellswere transformed with pRB474-tarS
or pRB474-tarP (isolated from E. coli DC10B) through
electroporation with a Bio-Rad Gene Pulser II (100 ohm, 25
μF, 2.5 kV). After recovery, bacteria were plated on Todd-
Hewitt agar supplemented with 10 μg/mL chloramphenicol to
select plasmid-complemented colonies. The presence of tarS or
tarP was confirmed by PCR analysis, using the primers for
TarP (up) 5′-CTTCACGAAAGAGCACTAGAAG-3′ and
TarP (dn) 5′-TTCCCGGCAAGTTGGTG-3′ and for TarS
(up) 5′- GTGAACATATGAGTAGTGCGTA-3′ and TarS
(dn) 5′-CATAATGTCCTTCGCCAATCAT-3′. The corre-
sponding WTA glycoform of complemented strains was also
verified by bacterial staining with WTA-specific Fab fragments,
followed by staining with goat F(ab’)2 anti-human kappa-Alexa
Fluor 647 (5 μg/mL, Southern Biotech) (Supporting Figure
1A).
Bacterial Binding to Recombinant Human Langerin.
Bacteria were grown to midexponential phase as described
above and collected by centrifugation (10 min, 4000 rpm).
Supernatant was discarded, and bacteria were resuspended to
an OD600 of 0.4, which corresponds to approximately 10
8
colony forming units (CFU)/mL in TSM buffer (2.4 g/L Tris
(Roche), 8.77 g/L NaCl (Sigma-Aldrich), 294 mg/L CaCl2·
2H20 (Merck), 294 mg/L MgCl2·6H20 (Merck), pH 7.4)
containing 0.1% bovine serum albumin (BSA, Merck). Next,
bacteria were incubated at 37 °C for 30 min with FITC-labeled
human langerin-extracellular domain (ECD) constructs,
referred to as human langerin-FITC, as previously de-
scribed.21,35 Bacteria were washed once with TSM 0.1%
BSA, fixed in 1% formaldehyde in PBS, and analyzed by flow
cytometry on a FACSverse (BD Biosciences). Per sample,
10 000 gated events were collected, and data were analyzed
using FlowJo 10 (FlowJo, LLC).
Recombinant Expression of Monoclonal Antibodies
and Fab Fragments. For monoclonal antibody expression,
we cloned the human IgG1 heavy chain (hG) and kappa light
chain (hK) constant regions (sequences as present in pFUSE-
CHIg-hG1 and pFUSE2-CLIg-hk; Invivogen) in the XbaI-AgeI
cloning site of the pcDNA34 vector (Thermo Fisher). VH and
VL sequences from monoclonal antibodies specific for α-
GlcNAc-WTA (4461), β-GlcNAc-WTA (4497) and β-1,4-
GlcNAc-WTA (6292) were derived from patent WO 2014/
193722 A1.50 As the VL of anti-WTA antibody 6292 resulted
in precipitation problems, it was adapted toward a Vκ3, leaving




and VL sequences, preceded by a Kozak sequence (ACCACC)
and the HAVT20 signal peptide (MACPGFLWALVIST-
CLEFSMA), were codon optimized for human expression
and ordered as gBlocks (IDT). We cloned VH and VL gBlocks
into the pcDNA34 vector, upstream of the IgG1 heavy chain
(hG) and kappa light chain (hK) constant regions,
respectively, by Gibson assembly (New England Biolabs)
according to the manufacturer’s instructions. NheI and BsiWI
were used as the 3′ cloning sites for VH and VL, respectively,
to preserve the immunoglobulin heavy and kappa light chain
amino acid sequence. The constructs were transformed in E.
coli TOP10F′ by heat shock, and clones were verified by PCR
and Sanger sequencing (Macrogen). Plasmids were isolated by
NucleoBond Xtra Midi kit (Macherey-Nagel) and sterilized
using 0.22 μm Spin-X centrifuge columns (Corning). We used
EXPI293F cells (Thermo Fisher), grown in EXPI293
Expression medium (Thermo Fisher) at 37 °C, 8% CO2 in
culture filter cap conical flasks (Sigma) on a rotation platform
(125 rotations/min) for protein production. One day before
transfection, cells were diluted to 2 × 106 cells/mL, and 100
mL cell culture was used for transfection the next day. In 10
mL of Opti-MEM (Thermo Fisher), 500 μL PEI-max (1 μg/
μL; Polysciences) was mixed with DNA (1 μg/mL cells) in a
3:2 ratio of hK and hG vectors. After 20 min of incubation at
room temperature, this DNA/PEI mixture was added dropwise
to 100 mL of EXPI293F cells. After 5 days, we verified IgG
expression by SDS-PAGE and harvested cell supernatant by
centrifugation and subsequent filtration through a 0.45 μM
filter. IgG was purified using a HiTrap Protein A column (GE
Healthcare) and Äkta Pure (GE Healthcare). Protein was
eluted in 0.1 M citric acid, pH 3.0, and neutralized with 1 M
Tris, pH 9.0. The IgG fraction was dialyzed overnight against
PBS at 4 °C. Purified monoclonal antibodies were stored at
−20 °C. Fab fragments specific for α-GlcNAc-WTA (4461), β-
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GlcNAc-WTA (4497), and β-1,4-GlcNAc-WTA (6292) were
cloned and expressed similar as the full-length monoclonal
antibodies, except that the Fab heavy chain ends with
211VEPKSC216. A flexible linker (GGGGS), an LPETG, and a
6xHIS tag were added at the C-terminus of each Fab.
EXPI293F expression supernatant was dialyzed against 50 mM
Tris, 500 mM NaCl; pH 8.0, before Fab purification on a
HISTrap FF column (GE Healthcare). Fab fragments were
dialyzed against 50 mM Tris, 300 mM NaCl; pH 8.0 and
stored at −20 °C.
Production of Biotinylated Ribitolphosphate (RboP)
Hexamer (6-) and Dodeca (12-)mer. Biotinylated RboP
hexamers were synthesized as described previously.24,32 The
synthesis of biotinylated RboP dodecamers and chemically
defined glycosylated RboP hexamers will be described in detail
elsewhere (S. Ali et al, paper in preparation).
Enzymatic Glycosylation of RboP Oligomers. Re-
combinant TarP protein and transformed E. coli TOP10F’
strains with pBAD-tarM or pBAD-tarS were kindly provided by
Prof. Thilo Stehle (University of Tübingen, Germany).32,51
Biotinylated RboP oligomers (0.17 mM) were incubated with
recombinant glycosyltransferases TarS, TarP or TarM (6.3 μg/
mL) for 2 h at room temperature with UDP-GlcNAc (2 mM,
Merck) in glycosylation buffer (15 mM HEPES, 20 mM NaCl,
1 mM EGTA, 0.02% Tween 20, 10 mM MgCl2, 0.1% BSA, pH
7.4). Glycosylated RboP hexamers were coupled to beads by
adding 5 × 107 Dynabeads M280 Streptavidin (Thermo Fisher
Scientific) to the individual glycosylation reaction mixtures.
After incubation for 15 min at room temperature, the coated
beads were washed three times with PBS 0.1% BSA 0.05%
Tween-20 using a magnetic sample rack and stored at 4 °C.
Recombinant Langerin Binding to Synthetic WTA.
Maxisorb plates (Nunc) were coated with 10 μg/mL his-
tetrameric-streptavidin-LPETG overnight at 4 °C, which was
expressed and isolated from a pColdl-Stav-LPETG vector
kindly provided by Tsutomu Tanaka (Kobo University, Japan).
The plates were washed three times with TSM 0.05% Tween-
20 (TSMT) and subsequently blocked with TSM 1% BSA for
1 h at 37 °C. After three washing steps with TSMT, a 50-fold
dilution of the glycosylation mixture described above
(corresponding to 3 uM RboP 6-mer or 12-mer) was added
to the plates and incubated for 1 h at 37 °C. Next, the plates
were washed with TSMT and further incubated with a
concentration range of recombinant human langerin-FITC for
30 min at 37 °C. For blocking experiments, mannan (20 μg/
mL) or EGTA (10 mM) were added immediately prior to
addition of recombinant human langerin-FITC. Finally, after
three washing steps, the plates were analyzed for langerin
binding using a Clariostar plate reader (BMG Labtech;
excitation 495 nm, emission 535 nm, gain 2000).
Cell Culture and muLC Differentiation. MUTZ-3 cells
(ACC-295, DSMZ) were provided by Prof. T. de Gruijl
(Amsterdam UMC, The Netherlands). Cells were maintained
at a cell density of 0.5−1 × 106 cells/mL in 12-well tissue
culture plates (Corning) in MEM-alpha (Gibco) with 20%
FBS (Hyclone), 1% glutaMAX (Gibco), 10% spent medium
from the renal carcinoma cell line 5637 (ACC-35, DSMZ) and
100 U/mL penicillin−streptomycin (Gibco). Cells were
routinely cultured at 37 °C with 5% CO2. Differentiation of
MUTZ-3 cells into MUTZ-3-derived LCs (muLCs) was
performed according to described protocols.52,53 In short,
MUTZ-3 cells were differentiated in the presence of 100 ng/
mL GM-CSF (Genway Biotech), 10 ng/mL TGF-β (R&D
Systems), and 2.5 ng/mL TNF-α (R&D Systems) for 11 days.
Twice a week, half of the medium was replaced with fresh
medium and double concentration of cytokines. To verify the
differentiated muLC phenotype, cells were analyzed by flow
cytometry for expression of CD207 (clone DCGM4, Beckman
Coulter) and CD1a (clone Hl149, BD Biosciences) as well as
the absence of CD34 (clone 581, BD Biosciences).
THP-1 cells, transfected with a lentiviral human langerin
construct or empty vector, were cultured in RPMI-1640
(Lonza) supplemented with 10% heat-inactivated FBS and 100
U/mL penicillin-streptomycin (Gibco) as described in.21
Binding and Internalization of WTA Beads or S.
aureus by Langerin-Expressing Cells. Dynabeads-M280
Streptavidin (Thermo Fisher Scientific) and midexponential S.
aureus (OD600 = 0.6−0.7) were labeled with 0.5 mg/mL FITC
(Sigma) in PBS for 30 min at 4 °C. After extensive washing
and coating of the beads with glycosylated RboP hexamers as
described above, beads and bacteria were resuspended in
RPMI 0.1% BSA at a concentration of 5 × 107 beads/mL or 1
× 108 CFU/mL (OD600 = 0.4), respectively. Bacteria were
stored at −20 °C and beads at 4 °C in the dark. For binding
experiments, 1 × 105 cells (THP-1 cells or muLCs) were
incubated with FITC-labeled WTA beads or FITC-labeled S.
aureus at different ratios in RPMI 0.1% BSA for 30 min at 4 °C.
Cells were washed (300g for 10 min at 4 °C), fixed in PBS 1%
formaldehyde, and analyzed by flow cytometry as described
above. To quantify internalization of β-GlcNAc WTA beads by
THP-1 cells, we incubated WTA beads with 2 × 105 cells in
RPMI 0.1% BSA at a bead-to-cell ratio of 1 for 30 min at 4 °C.
Cells were washed twice to remove unbound beads, and the
sample was divided over two separate tubes. Both samples
were incubated for an additional 30 min, one at 4 °C and the
other at 37 °C with 5% CO2 to allow phagocytosis. Cells were
washed, and Fc-receptors were blocked with recombinant
FLIPR-like (6 μg/mL) for 15 min at 4 °C.54 Next, monoclonal
antibodies specific for β-GlcNAc or α-GlcNAc WTA (4497/
4461-IgG1, respectively) were added to all samples at 3 μg/mL
for 20 min at 4 °C, followed by goat antihuman kappa-Alexa
Fluor 647 (5 μg/mL, Southern biotech) for another 20 min at
4 °C to allow discrimination between cell adherent (FITC
+/Alexa fluor 647+) and internalized beads (FITC+/Alexa
fluor 647-). Finally, cells were washed and fixed in 1%
formaldehyde in PBS. The internalized fraction was calculated
from the loss of Alexa Fluor 647 signal of FITC+ cells by flow
cytometry, as previously described.36
To confirm bead internalization by confocal microscopy,
cells were stained with WGA-Alexa Fluor 647 (Thermo Fisher
Scientific) and DAPI (Sigma) following incubation for 30 min
at 37 °C with FITC-labeled WTA beads and coated on 8 well
chamber slides glass slides (Ibidi) before analysis by confocal
laser scanning microscopy (SP5, Leica).
muLC Stimulation. Gamma-irradiation of S. aureus and
stimulation of muLCs was performed as previously de-
scribed.21 Briefly, S. aureus strains were grown to exponential
phase, washed with PBS, concentrated 10-fold in PBS with
17% glycerol, and stored at −80 °C. Gamma irradiation of
bacteria was performed at Synergy Health Ede B.V., a STERIS
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company (Ede, The Netherlands). The loss of viability was
confirmed by plating, and the bacterial concentrations were
calculated using the MACSQuant Analyzer 10.
muLCs (1 ×105) were stimulated with γ-irradiated RN4220
ΔtarMS+ptarS, RN4220 ΔtarMS+ptarP, or RN4220 ΔtarMS
+ptarM at bacteria to cell ratios of 0, 1, 10, and 50 for 24 h at
37 °C with 5% CO2 in IMDM containing 10% FBS.
Supernatants for cytokine analysis were collected after
centrifugation (300g, 10 min at 4 °C), and stored at −80 °C
until further analysis. Cells were washed with PBS 0.1% BSA,
stained with CD83 (clone HB15e) and CD86 (clone IT2.2,
Sony Biotechnology), fixed, and analyzed by flow cytometry.
Cytokine production was analyzed by ELISA for IL-8
(Sanquin) and TNFα (Thermo Fisher) following manufac-
turer’s instructions.
Statistical Analysis. Flow cytometry data were analyzed
using FlowJo 10 (FlowJo, LLC). All data were analyzed using
GraphPad Prism 8.3 (GraphPad Software) with a two-way
ANOVA followed by a Dunnett’s multiple comparison test
except for bacterial binding to langerin-FITC at one fixed
concentration for which one-way ANOVA was performed with
Dunnett’s multiple comparison test. p-Values are depicted in
the figures, and p < 0.05 was considered significant.
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